Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples